Chimeric Therapeutics Limited
CHMMF
$0.001
-$0.029-96.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 1.36M | 3.12M | 4.85M | 6.51M | 8.18M |
| Total Revenue | 1.36M | 3.12M | 4.85M | 6.51M | 8.18M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.36M | 3.12M | 4.85M | 6.51M | 8.18M |
| SG&A Expenses | 5.77M | 6.04M | 6.28M | 7.27M | 8.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.00M | 13.33M | 13.59M | 14.75M | 16.04M |
| Operating Income | -11.65M | -10.21M | -8.74M | -8.24M | -7.86M |
| Income Before Tax | -11.60M | -9.94M | -8.25M | -8.08M | -8.03M |
| Income Tax Expenses | 145.50K | 76.80K | 6.70K | -24.40K | -55.50K |
| Earnings from Continuing Operations | -11.75 | -10.02 | -8.26 | -8.06 | -7.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.75M | -10.02M | -8.26M | -8.06M | -7.98M |
| EBIT | -11.65M | -10.21M | -8.74M | -8.24M | -7.86M |
| EBITDA | -10.93M | -9.49M | -8.03M | -7.57M | -7.21M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 3.68B | 3.23B | 2.78B | 2.39B | 1.99B |
| Average Diluted Shares Outstanding | 3.68B | 3.23B | 2.78B | 2.39B | 1.99B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |